Nov 16, 2004 · Relapsed AML after allogeneic SCT has a poor prognosis. So far, no standard therapy could be defined. Donor lymphocyte transfusion (DLT) has ...
We retrospectively evaluated overall survival (OS) of 489 adults with de novo AML in hematological relapse after SCT, receiving DLT (n=190) or not (n=299). ... 5 ...
We retrospectively evaluated overall survival (OS) of 489 adults with de novo AML in hematological relapse after SCT, receiving DLT (n=190) or not (n=299). ... 5 ...
Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1 year, 2 years, and 5 ...
Missing: comparison 489
Oct 1, 2007 · Estimated survival at 2 years (+/- standard deviation) was 21% +/- 3% for patients receiving DLI and 9% +/- 2% for patients not receiving DLI.
Missing: 489 | Show results with:489
People also ask
What percentage of AML patients relapse after stem cell transplant?
Can leukemia relapse after stem cell transplant?
Can AML come back after transplant?
What is donor lymphocyte infusion for AML relapse?
Clinical applications of donor lymphocyte infusion from an HLA ...
haematologica.org › article › view
Jan 1, 2020 · Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Donor lymphocyte infusions (DLI), likewise a second allo-HCT, have become a standard approach to treat AML and MDS relapses post allo-HCT.
Jan 5, 2023 · Second alloHSCT and infusion of donor lymphocytes (DLI) represent the only established treatment options with the potential for cure.
A total 143 patients with AML who received DLI for treatment of a first hematological relapse after allogeneic. HSCT were included in the study (Table 1). The ...
Missing: 489 | Show results with:489
Independent of donor, 74% of patients achieved complete remission after HSCT2, and half of these patients experienced relapse again. Overall survival (OS) at 2 ...